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reported. Mornet reported 16 new missense mutations in European 
patients (i.e., S-1F, A23V, R58S, G103R, G112R, N153D, R167W, 
R206W, W253X, E274K, S428P, R433C, G456S, G474R and splice 
mutations in intron 6 and 9) [1,2].
ALPL mutations cause mineralization disorders including soft 
bones (rickets or osteomalacia) and defects in teeth as consequence 
of a reduced TNSALP activity.
The disease is classified by patient age when the first signs 
and symptoms manifest and by mode of inheritance (autosomal 
dominant/recessive): benign prenatal, lethal perinatal, infantile, 
childhood, adult and odonto- HPP [2,3]. The more severe forms of 
HPP (perinatal lethal/infantile) are transmitted as autosomal recessive 
traits and are due to ALPL mutations which impair TNSALP almost 
completely. Infantile HPP has been defined as a disease presenting 
symptoms before 6 months of age and Pyridoxine-responsive 
seizures often occur. The patients with the infantile form are affected 
also by respiratory complications and premature craniosynostosis 
due to the high intracranial pressure.
Several therapeutic approaches have been tested for patients 
with HPP including bone marrow, bone fragments and osteoblasts 
transplantation, parathyroid hormone administration, enzyme 
replacement therapy (ERT) with alkaline phosphatase (ALP)-rich 
serum obtained from patients affected by Paget’s disease, infusion 
of plasma from healthy individuals or purified ALP [4,5]. The ERT, 
however, requires repeated subcutaneous administration of the 
enzyme, due to its short half-life in serum. Recently, clinical phase 
2 studies with enzyme-replacement therapy with recombinant 
TNSALP have been perfomed [6]. Unfortunately, the variety 
of attempted treatments has obtained only limited clinical and 
radiographic improvements and no established therapeutic approach 
exists for HPP.
Bone formation
Endochondral bone formation is performed by osteoblasts 
that mineralize the extracellular matrix. This process includes the 
formation of crystalline hydroxyapatite in the matrix vesicles and 
matrix modulation to induce the propagation of apatite outside 
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Background
HPP was first described in 1948 and has therefore been known for 
a long time as an inherited disorder of bone and mineral metabolism. 
HPP is a rare inborn error of metabolism due to mutations in ALPL 
gene located on chromosome 1 which encodes the tissue non-
specific alkaline phosphatase isozyme. This gene is subject to high 
allelic heterogeneity and more than 260 ALPL missense mutations 
causing suboptimal activity of TNSALP have been identified. They 
are reported in a dedicated database (http://www.sesep.uvsq.
fr/03_hypo_mutations.php). The first identified mutation was a 
homozygous missense in exon 6 of the ALPL gene, A162T.9. Later, 
new mutations, (i.e., R54C, R54P, E174K, Q190P, Y246H, D277A, 
D361V, Y419H, G317D2; E281K, A160T, F310L, G439R12, two 
frameshift mutations at positions 328 and 50313, respectively) were 
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these vesicles. Among other factors, such as Ca2+ concentration and 
fibrillar collagen production, bone mineralization depends on the 
balance of inorganic phosphate (Pi) and inorganic pyrophosphate 
(PPi), a mineralization inhibitor. The osteoblastic molecules affecting 
bone mineral apposition by regulating the extracellular levels of PPi 
are TNSALP, NPP1 (nucleotide pyrophoshatase/phosphodiesterase 
isozyme) and the ANK gene product. In normal individuals, 
TNSALP functions as an ecto-enzyme, located on the outer surface 
of matrix vesicles of osteoblasts and chondrocytes where it hydrolizes 
the inorganic pyrophosphate (PPi), pumped extracellularly by the 
protein ANK or produced extracellularly by nucleoside triphosphate 
pyrophosphatase (NPP1) [2]. NPP1, a glycoprotein encoded by 
ENPP1 gene, is highly expressed by osteoblast and chondrocyte 
cells; it inhibits matrix mineralization by hydrolyzing extracellular 
nucleotides into inorganic pyrophosphate (PPi), a natural substrate 
of TNSALP [7] (Figure 1).
Many studies have shown that most of the ALPL mutations 
present in severe hypophosphatasia lead to the production of a mutant 
TNSALP protein unable to reach the cellular membrane, which 
accumulates in the Golgi apparatus and is subsequently degraded 
by the proteasome. In mild hypophosphatasia, on the contrary, the 
protein is to some extent- correctly located at the cell membrane.
The accumulation of extracellular PPi due to the reduced catalytic 
activity of mutant TNSALP found in HPP causes the pathogenetic 
block of bone mineralization and leads a disturbance of calcium and 
Pi homeostasis.
MSCs and bone diseases
Lately an increasing interest has arisen in the possible employment 
of MSCs for the treatment of bone defects. MSC contribution to bone 
fracture repair has been extensively documented; scaffolds seeded with 
MSCs are most often used in tissue engineering [8,9]. Treatments of 
bone diseases with MSCs have been tested in osteogenesis imperfecta, 
osteonecrosis of the femoral head, osteoporosis, rheumatoid arthritis, 
osteoarthritis and, recently, in HPP [10]. MSCs are multipotent cells 
and can differentiate in adipocytes, osteoblasts and chondrocytes. 
These cells can be selected from different tissues as bone marrow, 
dental pulp, adipose tissue, as well as placenta, amniotic fluid and 
umbilical cord blood [11]; they can be isolated from peripheral 
blood too [12]. When MSCs are administrated in vivo they migrate 
to damaged tissues to replace defective cells and they can also induce 
peripheral tolerance [13]. In fact, MSCs reduce graft versus-host 
disease (GVHD) by regulating T cells, B cells, natural killer cells, 
monocytes, and dendritic cells [14]. The ability of MSCs to migrate is 
due to several chemokines and their related receptors such as PDGF 
(platelet-derived growth factor)/PDGF receptor, SDF-1 (stromal 
cell-derived factor 1)/ CXCR4(CXC chemokine receptor type, 4) 
axis, SCF (stem cell factor) /c-kit axis, VEGF (vascular endothelial 
growth factor/VEGF receptor, MCP-1(monocyte chemo-attractant 
protein-1)/C-C chemokine receptor type 2 [15]. Furthermore, MSC 
can be modified to carry therapeutic genes, serving as programmed 
molecule transmitters [16]. All these features make MSCs appealing 
for a therapeutic use in pathologies involving bone defects. Still much 
research needs to be done: their potential for bone regeneration is 
clear but the focus is on how to use MSC clinically. In order to reach 
this goal a thorough understanding of the pathways involved in stem 
cells differentiation is essential.
MSCs and HPP
Several clinical trials have reported an improvement of skeletal 
mineralization following bone marrow transplantation (BMT) in 
genetic disorders such as osteogenesis imperfecta [17]. Positive 
effects have been demonstrated also in HPP patients receiving bone 
marrow cells [18]. The beneficial effects of BMT are ascribable to the 
presence of MSCs and their inherent multipotency. BMT, as well as 
infusions with BM stromal cells or cultured osteoblasts performed in 
HPP patients, nevertheless, showed limited efficacy, while there was 
no direct evidence that these procedures led to new bone formation 
[19,20]. In particular, Cahill et al transplanted bone fragments and 
cultured osteoblasts but less than 1% of allogeneic cells were found in 
HPP bone 20 months after transplantation [19].
Recent approaches have suggested that BMT in combination with 
additional infusions of in vitro expanded MSCs improved patients’ 
conditions as well as skeletal mineralization. Taketani et al. reported 
an unfortunate case where a combination of MSC with Fludarabine/
cyclophosphamide used for the treatment of HPP caused leukemia 
with minor BCR-ABL (Ph+) in a 32-month-old girl. The authors 
yet suggested that alkaline phosphatase deficiency per se was not 
responsible for the malignancy [21]. Another study reported a 
complex approach consisting of expanded allogeneic MSCs, infused 
jointly with in vitro MSC-derived osteoblasts [22]. The authors 
observed poor bone mineralization and persistent low TNSALP 
serum levels. Recently, the same authors have used a different 
approach in two patients with severe HPP by combining BMT and ex 
vivo expanded MSCs (MSCT) [23]. The donors were first- or second-
degree relatives with normal serum TNSALP levels and no mutations 
in ALPL gene. The clinical conditions improved in both patients after 
a single allogeneic BMT followed by multiple allogeneic MSCT. Bone 
mineralization as well as muscle mass increased in both patients 
although serum TNSALP levels did not normalize. Their respiratory 
capacity increased and their psychophysical development improved. 
The development of bone architecture was nevertheless abnormal.
Katsube et al. devised an intriguing approach to restore HPP 
MSCs functions by means of gene therapy [24]. The authors 
transduced a vector containing the promoter-driven ALPL gene in 
bone marrow-MSCs of a HPP patient. The restoration of cellular 
functions was demonstrated by transplantation of the engineered 
MSCs in nude rats. In rats the cells survived in subcutaneous sites for 
at least 6 weeks and were able to differentiate into osteoblasts, hence 
producing new bone. Further studies need to be performed in order 
to evaluate the efficacy of this promising therapeutic approach, which 
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Figure 1: Schematic representation of molecules involved in Pi/PPi 
balance and mineralization process in matrix vesicles. TNSALP: Tissue 
non specific alkaline phosphatase, NPPI: Ectonucleotide Pyrophosphatase 
Phosphodiesterase 1, ANK: Ankylosis Protein, HA: Hydroxyapatite, Pi: 
Inorganic phosphate, PPi: Inorganic pyrophosphate.
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configures the possibility to employ genetically modified autologous 
MSCs for the treatment of HPP or other genetic skeletal diseases.
Conclusion
The therapeutic promise of MSCs for bone-related disorders 
is rising [25] but, in spite of the benefits associated to MSCT so far 
reported, further studies are needed to evaluate the molecular processes 
involved in MSCs engraftment and their osteogenic differentiation in 
HPP patients. Understanding the mechanisms through which MSCT 
acts in these patients can help to identify the most effective approach 
suitable to restore bone architecture and functions not only for HPP 
but also for other skeletal related diseases.
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